Author

G. Bix

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cell Biology· 1 Immunology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Organism:human· 2 Research Focus:drug response / drug discovery· 1 Organism:mouse· 1

Frequent Co-Authors

P. P. Chapagain· 2 shared T. E. Gressett· 2 shared A. Narayanappa· 1 shared B. Beddingfield· 1 shared C. J. Roy· 1 shared D. Nader· 1 shared E. B. Engler-Chiurazzi· 1 shared I. C. Murray-Brown· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 19 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCell Biology

P. P. Chapagain

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

A dual-receptor mechanism between integrins and ACE2 widens SARS-CoV-2 tissue tropism

D. Nader, T. E. Gressett, M. L. Hossen, P. P. Chapagain, S. W. Kerrigan, G. Bix

The paper investigates a dual-receptor mechanism involving integrins and ACE2 for SARS-CoV-2 entry and signaling, highlighting integrin's role in expanding tissue tropism and inflammation.

bioRxiv · Jan 2, 2022 · PreprintCell Biology

In-vivo Protection from SARS-CoV-2 infection by ATN-161 in k18-hACE2 transgenic mice

A. Narayanappa, E. B. Engler-Chiurazzi, I. C. Murray-Brown, T. E. Gressett, I. J. Biose, W. H. Chastain, G. Bix

This study evaluates the therapeutic potential of ATN-161 in reducing SARS-CoV-2 infection in mice by inhibiting integrin 5β1, showing reduced viral load and improved lung histology.

bioRxiv · May 8, 2021Immunology

The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection

B. Beddingfield, N. Iwanaga, P. P. Chapagain, W. Zheng, C. J. Roy, T. Y. Hu, J. Kolls, G. Bix

This paper explores ATN-161 as a potential therapy for SARS-CoV-2 by targeting the interaction between the spike protein and 5β1 integrin, alongside ACE2.

bioRxiv · Jun 15, 2020Microbiology